EE186 Cost-Utility of Nivolumab Versus Observation for the Adjuvant Treatment of Urothelial Carcinoma (UC) for Patients Who Are at High-Risk of Recurren A United States (US) Payer Perspective
Jul 1, 2022, 00:00 AM
10.1016/j.jval.2022.04.435
https://www.valueinhealthjournal.com/article/S1098-3015(22)00636-2/fulltext
Section Title :
Section Order :
10383
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00636-2&doi=10.1016/j.jval.2022.04.435